Related references
Note: Only part of the references are listed.Effective presentation of immunogenicity risk assessments and related data in regulatory dossiers
Paul Chamberlain
BIOANALYSIS (2019)
Evaluation of potential biotin interference in immunogenicity testing
Alexander Poehler et al.
BIOANALYSIS (2019)
Evaluation of in-study cut points to enable appropriate interpretation of clinical immunogenicity results
Jochen Brumm et al.
BIOANALYSIS (2019)
Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH
Jihua Chen et al.
BIOANALYSIS (2019)
Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing
Hao Jiang et al.
BIOANALYSIS (2019)
Nonclinical immunogenicity risk assessment of therapeutic proteins
Sophie Tourdot et al.
BIOANALYSIS (2019)
Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials
Montserrat Carrasco-Triguero et al.
BIOANALYSIS (2019)
Current challenges in assessing immunogenicity
Gopi Shankar
BIOANALYSIS (2019)
Harmonization and standardization of immunogenicity assessment of biotherapeutic products
Meenu Wadhwa et al.
BIOANALYSIS (2019)
Compatibility of immunogenicity guidance by the EMA and the US FDA
Pekka Kurki
BIOANALYSIS (2019)
Share Paper
